强直性脊柱炎患者对英夫利西单抗治疗的支付意愿研究
该研究基于参加EASIC开放标签延伸试验的85例强直性脊柱炎患者,采用假设场景调查患者的支付意愿(WTP)。结果显示74.1%的患者愿意支付,愿意支付者每次给药平均支付€275(中位数€100,IQR €50-200)。ASAS20应答与更低的零支付意愿(OR 0.14,95%CI 0.03-0.71)及更高的支付金额(exp(β)=3.32,95%CI 1.44-7.69)相关。
要点
- 74.1%的强直性脊柱炎患者愿意为英夫利西单抗治疗自付费用。
- ASAS20应答者零支付意愿更低且支付金额约为无应答者的3倍。
- 居住国家和年龄增长也与支付意愿或金额相关。
核心结论
- 在假设场景下,约四分之三接受长期英夫利西单抗治疗的强直性脊柱炎患者表示愿意自付部分费用。
- 治疗应答既影响患者是否愿意支付,也影响其愿意支付的金额。
研究设计与样本
- 研究使用参加欧洲AS英夫利西单抗队列(EASIC)开放标签延伸试验(ASSERT研究延伸)的85例强直性脊柱炎患者数据。
- 支付意愿在EASIC基线时通过假设场景调查纳入,询问患者是否愿意为英夫利西单抗的获益支付及每次给药愿意支付的金额。
- 采用零膨胀负二项回归(ZINB)探索与支付意愿相关的因素。
主要发现
- 85例患者中63例(74.1%)愿意支付。
- 愿意支付者每次给药平均支付€275(中位数€100,四分位距€50-200)。
- 多变量ZINB分析显示,ASAS20应答与支付0欧元的可能性降低7倍相关(OR 0.14,95%CI 0.03-0.71)。
- ASAS20应答与愿意支付金额增加3倍相关(exp(β)=3.32,95%CI 1.44-7.69)。
- 居住国家与支付0欧元的可能性降低相关(OR 0.07,95%CI 0.02-0.36),年龄增长与愿意支付金额相关(exp(β)=1.05,95%CI 1.01-1.09)。
临床怎么用
- 临床中可关注治疗应答对患者支付意愿的影响,ASAS20应答者可能更愿意为治疗自付费用。
- 患者年龄和居住国家可能影响其支付意愿,在医患沟通中可考虑这些因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open-label extension of the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) were used. WTP was included at baseline in EASIC and comprised a hypothetical scenario exploring whether the patient would be willing to pay for beneficial effects of infliximab and, if so, what amount they would be willing to pay per administration. Factors associated with WTP were explored using zero-inflated negative binomial (ZINB) regressions. RESULTS: Of the 85 patients, 63 (74.1%) were willing to pay, and among these, the mean amount they were willing to pay per administration was €275 (median €100 [interquartile range €50-200]). Multivariable ZINB analysis showed that Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response was associated with a 7-fold lower likelihood to pay 0 euros (odds ratio [OR] 0.14 [95% confidence interval (95% CI) 0.03-0.71]) and a 3-fold increase in the amount willing to pay (exp(β) = 3.32 [95% CI 1.44-7.69]). In addition, the country of residence was associated with a lower likelihood to pay 0 euros (OR 0.07 [95% CI 0.02-0.36]), while increased age was associated with the amount willing to pay (exp(β) = 1.05 [95% CI 1.01-1.09]). CONCLUSION: In a hypothetical scenario, three-quarters of patients with AS receiving long-term infliximab stated that they were willing to pay an out-of-pocket contribution for this treatment. Treatment response contributed to the willingness as well as to the amount patients were willing to pay.
引用
- Webers C, Essers I, van Tubergen A, et al. Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness-to-Pay Approach. Arthritis Care Res (Hoboken). 2018. PMID: 28575536. doi:10.1002/acr.23299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。